Effective photothermal chemotherapy with docetaxel-loaded gold nanospheres in advanced prostate cancer

Shen, Yunli; Ma, Zhi-Ya; Chen, Fei; Dong, Qingjian; Hu, Qiran; Bai, Ling-Yu; Chen, Jing

doi:10.3109/1061186x.2015.1018910

Cited by 14 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, 300 μl of 1% chloroauric acid (HAuCl4•3H2O) (Sigma-Aldrich, Oakville, ON, Canada) was added to 30 mL of NP transport is heavily dependent on the MT network. Hence, the MT network is a good target for modulating NP dynamics to improve therapeutics [27,28]. If we were to successfully integrate both DTX and NPs into any NP-driven therapeutic approach, the following questions need to be answered: (a) Does NP size matter?…”

Section: Gnp Preparation and Modificationmentioning

confidence: 99%

Modulation of the Microtubule Network for Optimization of Nanoparticle Dynamics for the Advancement of Cancer Nanomedicine

et al. 2020

View full text Add to dashboard Cite

Nanoparticles (NPs) have shown promise in both radiotherapy and chemotherapy. NPs are mainly transported along cellular microtubules (MTs). Docetaxel (DTX) is a commonly used chemotherapeutic drug that can manipulate the cellular MT network to maximize its clinical benefit. However, the effect of DTX on NP behaviour has not yet been fully elucidated. We used gold NPs of diameters 15 and 50 nm at a concentration of 0.2 nM to investigate the size dependence of NP behaviour. Meanwhile, DTX concentrations of 0, 10 and 50 nM were used to uphold clinical relevance. Our study reveals that a concentration of 50 nM DTX increased NP uptake by ~50% and their retention by ~90% compared to cells treated with 0 and 10 nM DTX. Smaller NPs had a 20-fold higher uptake in cells treated with 50 nM DTX vs. 0 and 10 nM DTX. With the treatment of 50 nm DTX, the cells became more spherical in shape, and NPs were redistributed closer to the nucleus. A significant increase in NP uptake and retention along with their intracellular distribution closer to the nucleus with 50 nM DTX could be exploited to target a higher dose to the most important target, the nucleus in both radiotherapy and chemotherapy.

show abstract

Section: Gnp Preparation and Modificationmentioning

confidence: 99%

Modulation of the Microtubule Network for Optimization of Nanoparticle Dynamics for the Advancement of Cancer Nanomedicine

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The currently developed FA-targeted drug delivery systems include various kinds of nanoparticles, e.g., liposomes, micelles, carbon nanotubes, nanorods, core-shell quantum dots, nanospheres, mesoporous nanoparticles and dendrimers (Table 1, Figure 2). The NP have been analysed for achieving an effective antitumour effect by several strategies: single drug delivery [42][43][44][45][46], co-delivery of more than one drug [47][48][49], co-delivery of drug and gene [50][51][52][53], phototherapy [54][55][56], systems combining cancer treatment and diagnosis [57][58][59][60][61] and gene delivery [53,62]. Some drug delivery systems use magnetic ions [63][64][65] or gold nanoparticles [66].…”

Section: Examples Of Folic Acid-targeted Nanoparticlesmentioning

confidence: 99%

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the major causes of death worldwide and its treatment remains very challenging. The effectiveness of cancer therapy significantly depends upon tumour-specific delivery of the drug. Nanoparticle drug delivery systems have been developed to avoid the side effects of the conventional chemotherapy. However, according to the most recent recommendations, future nanomedicine should be focused mainly on active targeting of nanocarriers based on ligand-receptor recognition, which may show better efficacy than passive targeting in human cancer therapy. Nevertheless, the efficacy of single-ligand nanomedicines is still limited due to the complexity of the tumour microenvironment. Thus, the NPs are improved toward an additional functionality, e.g., pH-sensitivity (advanced single-targeted NPs). Moreover, dual-targeted nanoparticles which contain two different types of targeting agents on the same drug delivery system are developed. The advanced single-targeted NPs and dual-targeted nanocarriers present superior properties related to cell selectivity, cellular uptake and cytotoxicity toward cancer cells than conventional drug, non-targeted systems and single-targeted systems without additional functionality. Folic acid and biotin are used as targeting ligands for cancer chemotherapy, since they are available, inexpensive, nontoxic, nonimmunogenic and easy to modify. These ligands are used in both, single- and dual-targeted systems although the latter are still a novel approach. This review presents the recent achievements in the development of single- or dual-targeted nanoparticles for anticancer drug delivery.

show abstract

“…Regarding PCa, PET (or PET/CT) and SPECT (or SPECT/CT) has been used in several NP applications [131,315,316,317,318,319,320,321]. For example, Pressley et al evaluated an amphiphilic NP for natriuretic peptide clearance receptor (NPRC) targeting and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelator for high specific activity 64 Cu PET-radiolabeling.…”

Section: Multimodal Imaging Options For Prostate and Breast Cancermentioning

confidence: 99%

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Elgqvist

2017

IJMS

View full text Add to dashboard Cite

Prostate and breast cancer are the second most and most commonly diagnosed cancer in men and women worldwide, respectively. The American Cancer Society estimates that during 2016 in the USA around 430,000 individuals were diagnosed with one of these two types of cancers, and approximately 15% of them will die from the disease. In Europe, the rate of incidences and deaths are similar to those in the USA. Several different more or less successful diagnostic and therapeutic approaches have been developed and evaluated in order to tackle this issue and thereby decrease the death rates. By using nanoparticles as vehicles carrying both diagnostic and therapeutic molecular entities, individualized targeted theranostic nanomedicine has emerged as a promising option to increase the sensitivity and the specificity during diagnosis, as well as the likelihood of survival or prolonged survival after therapy. This article presents and discusses important and promising different kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications. The presentation of different nanoparticles and theranostic applications is quite general, but there is a special focus on prostate cancer. Some references and aspects regarding breast cancer are however also presented and discussed. Finally, the prostate cancer case is presented in more detail regarding diagnosis, staging, recurrence, metastases, and treatment options available today, followed by possible ways to move forward applying theranostics for both prostate and breast cancer based on promising experiments performed until today.

show abstract

Effective photothermal chemotherapy with docetaxel-loaded gold nanospheres in advanced prostate cancer

Abstract: Loading chemotherapeutic drugs into MGNs can increase antitumor potency, reduce normal cell damage and decrease drug resistance, thus representing a promising approach for advanced prostate cancer treatment.

Cited by 14 publications

References 24 publications

Modulation of the Microtubule Network for Optimization of Nanoparticle Dynamics for the Advancement of Cancer Nanomedicine

Modulation of the Microtubule Network for Optimization of Nanoparticle Dynamics for the Advancement of Cancer Nanomedicine

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications—Focus on Prostate and Breast Cancer

Contact Info

Product

Resources

About